A Phase II clinical trial (NCT02576444, OLAPCO) is currently ongoing for olaparil combination therapy in cancer patients with PTEN, PIK3CA, AKT, or ARID1A mutations or other mutations that lead to dysregulation of the PI3K/AKT pathway. This evidence concerns the gene PTEN and cancer.